Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-m8s7h Total loading time: 0 Render date: 2024-07-18T21:01:20.735Z Has data issue: false hasContentIssue false

6 - Sapropterin treatment of phenylketonuria

from SECTION II - COFACTORS

Published online by Cambridge University Press:  17 November 2010

By
Barbara K. Burton
Edited by
Jess G. Thoene
Jess G. Thoene
Affiliation:
University of Michigan, Ann Arbor
Get access
Type
Chapter
Information
Small Molecule Therapy for Genetic Disease , pp. 76 - 85
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Centerwall, SA, Centerwall, WK. The discovery of phenylketonuria: The story of a young couple, two affected children and a scientist. Pediatrics. 2000;105:89–103CrossRefGoogle Scholar
Guthrie, R, Susi, A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics. 1963;32:338–343Google ScholarPubMed
,National Institutes of Health Consensus Development Panel:National Institutes of Health Consensus Development Conference Statement: Phenylketonuria: Screening and Management, Oct. 16–18, 2000. Pediatrics. 2001;108:972–982Google Scholar
Guldberg, P, Rey, F, Zschocke, J, Romano, V, François, B, Michiels, L, Ullrich, K, Hoffmann, GF, Burgard, P, Schmidt, H, Meli, C, Riva, E, Dianzani, I, Ponzone, A, Rey, J, Güttler, F. A European multicenter study of phenylalanine hydroxylase deficiency: Classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotypes. Am J Hum Genet. 1998;63:71–79CrossRefGoogle Scholar
Weglage, J, Pietsch, M, Feldmann, R, et al. Normal clinical outcome in untreated subjects with mild hyperphenylalaninemia. Pediatr Res. 2001;49:532–536CrossRefGoogle ScholarPubMed
Arnold, GL, Vladutiu, CJ, Orlowski, CC, Blakely, EM, DeLuca, J. Prevalence of stimulant use for attentional dysfunction in children with phenylketonuria. J Inherit Metab Dis. 2004;27:137–143CrossRefGoogle ScholarPubMed
Gassio, R, Fuste, E, Lopez-Sala, A, Artuch, R, Vilaseca, MA, Campistol, J. School performance in early and continuously-treated phenylketonuria. Pediatr Neurol. 2005;33:267–271CrossRefGoogle ScholarPubMed
Sullivan, JE, Chang, P. Emotional and behavioral functioning in phenylketonuria. J Pediatr Psychol. 1999;24:281–289CrossRefGoogle ScholarPubMed
Lee, PJ, Amos, A, Robertson, L, Fitzgerald, B, Hoskin, R, Lilburn, M, Weetch, E, Murphy, G. Adults with late diagnosed PKU and severe challenging behavior: A randomised placebo-controlled trial of phenylalanine-restricted diet. J Neurol Neurosurg Psychiatry. 2009;80(6):631–635CrossRefGoogle ScholarPubMed
Levy, HL, Ghavani, M. Maternal phenylketonuria: A metabolic teratogen. Teratology. 1996;53:176–1843.0.CO;2-2>CrossRefGoogle ScholarPubMed
Spronsen, FJ, Hoeksma, M, Reijngoud, DJ. Brain dysfunction in phenylketonuria: Is phenylalanine toxicity the only possible cause?J Inherit Metab Dis. 2009;32:46–51.CrossRefGoogle ScholarPubMed
Mitchell, JJ, Scriver, CR. Phenylalanine hydroxylase deficiency. Gene Reviews. 2007. Available from: www.genetests.org
Feillet, F, Clarke, L, Meli, C, Lipson, M, Morris, AA, Harmatz, P, Mould, DR, Green, B, Dorenbaum, A, Giovannini, M, Foehr, E; for the Sapropterin Research Group. Pharmacokinetics of sapropterin in patients with phenylketonuria. Clin Pharmacokinet. 2008;47:817–825CrossRefGoogle ScholarPubMed
Levy, HL, Burton, B, Cederbaum, S, Scriver, C. Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH4) in phenylketonuria and its use in treatment. Mol Genet Metab. 2007;92:287–291CrossRefGoogle Scholar
Burton, BK, Grange, DK, Milanowski, A, Vockley, G, Feillet, F, Crombez, EA, Abadie, V, Harding, CO, Cedarbaum, S, Dobbelaere, D, Smith, A, Dorenbaum, A. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): A phase II, multicentre, open-label, screening study. J Inherit Metab Dis. 2007;30:700–707CrossRefGoogle ScholarPubMed
Blau, N, Belanger-Quintana, A, Demirkol, M, Feillet, F, Giovannini, M, Macdonald, A, Trefz, FK, Spronsen, FV. Optimizing the use of sapropterin (BH4) in the management of phenylketonuria. Mol Genet Metab. 2009;96:158–163CrossRefGoogle Scholar
Levy, HL, Milanowski, A, Chakrapani, A, Cleary, M, Lee, P, Trefz, FK, Whitley, CB, Feillet, F, Feigenbaum, AS, Bebchuk, JD, Christ-Schmidt, H, Dorenbaum, A, Sapropterin, Research Group. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentrations in patients with phenylketonuria: A phase III randomised placebo-controlled study. Lancet. 2007;370:504–510CrossRefGoogle ScholarPubMed
Trefz, FK, Burton, BK, Longo, N, Casanova, MM, Gruskin, DJ, Dorenbaum, A, Kakkis, ED, Crombez, EA, Grange, DK, Harmatz, P, Lipson, MH, Milanowski, A, Randolph, LM, Vockley, J, Whitley, CB, Wolff, JA, Bebchuk, J, Christ-Schmidt, H, Hennermann, JB, Sapropterin, Study Group. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: A phase III, randomized double-blind, placebo-controlled study. J Pediatr. 2009;154:700–707CrossRefGoogle Scholar
Burlina, A, Blau, N. Effect of BH(4) supplementation on phenylalanine tolerance. J Inherit Metab Dis. 2009;32:40–45CrossRefGoogle ScholarPubMed
Sarkissian, CN, Gamez, A. Phenylalanine ammonia lyase, enzyme substitution therapy for phenylketonuria, where are we now?Mol Genet Metab. 2005;86(Suppl 1):S22–S26CrossRefGoogle ScholarPubMed
Matalon, R, Michals-Matalon, K, Bhatia, G, Burlina, AB, Burlina, AP, Braga, C, Fiori, L, Giovannini, M, Grechanina, E, Novikov, P, Grady, J, Tyring, SK, Guttler, F. Double blind placebo control trial of large neutral amino acids in treatment of phenylketonuria: Effect on blood phenylalanine. J Inherit Metab Dis. 2007;30:153–158CrossRefGoogle ScholarPubMed
Schindeler, S, Ghosh-Jerath, S, Thompson, S, Rocca, A, Joy, P, Kemp, A, Rae, C, Green, K, Wilcken, B, Christodoulou, J. The effects of large neutral amino acid supplements in PKU: An MRS and neuropsychological study. Mol Genet Metab. 2007;91:48–54CrossRefGoogle ScholarPubMed
Harding, C. Progress toward cell-directed therapy for phenylketonuria. Clin Genet. 2008;74:97–104CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×